Asian Pacific Journal of Cancer Prevention

  • 제15권14호
  • /
  • Pages.5551-5556
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Lack of Effects of HER-2/neu on Prognosis in Colorectal Cancer: a Meta-analysis

  • Han, Jun (Department of General Surgery, Zhongshan Hospital, Fudan University) ;
  • Meng, Qing-Yang (Department of General Surgery, Zhongshan Hospital, Fudan University) ;
  • Liu, Xiao (Nursing Department, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University) ;
  • Xi, Qiu-Lei (Department of General Surgery, Zhongshan Hospital, Fudan University) ;
  • Zhuang, Qiu-Lin (Department of General Surgery, Zhongshan Hospital, Fudan University) ;
  • Wu, Guo-Hao (Department of General Surgery, Zhongshan Hospital, Fudan University)
  • 발행 : 2014.07.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The prognostic value of human epidermal growth factor receptor-2 (HER-2/neu) for survival of patients with colorectal cancer (CRC) is still ambiguous. We therefore performed a meta-analysis to evaluate its prognostic significance. Materials and Methods: We searched the MEDLINE and EMBASE databases for published literature investigating associations between HER-2/neu status and overall survival of patients with CRC. A meta-analysis was performed using a DerSimonian-Laird model and publication bias was investigated by Begg's and Egger's tests. Subgroup analysis was also conducted according to the study design type, study quality score, cut-off value for HER-2/neu overexpression, publication region, patient number and publication year. Results: A total of 17 eligible studies involving 2,347 patients were identified for this meta-analysis. The combined hazard ratio (HR) was 1.31 (95% confidence interval (CI): 0.96-1.79), suggesting that HER-2/neu overexpression was not significantly associated with overall survival of patients with CRC. However, subgroup analysis revealed that HER-2/neu overexpression had an unfavorable impact on survival when the analysis was restricted to subgroups of study quality score ${\leq}5 $(HR=1.56, 95%CI: 1.17-2.10), Asian patients (HR=1.74, 95%CI: 1.22-2.49), patient number ${\leq}106$ (HR=1.57, 95%CI: 1.01-2.44), publication year before 2003 (HR=1.59, 95%CI: 1.02-2.49), and prospectively designed study (HR=3.62, 95%CI: 1.42-9.24). The effect disappeared in subgroups of study quality scores > 5 (HR=0.69, 95%CI: 0.33-1.44), non Asian patients (HR=1.14, 95%CI: 0.77-1.70), patients' number > 106 (HR=1.07, 95%CI: 0.67-1.72), publication year after 2003 (HR=1.13, 95%CI: 0.76-1.69), and retrospectively designed study (HR=1.22, 95%CI: 0.89-1.67). Conclusions: Our meta-analysis suggests that HER-2/neu overexpression might not be a significantly prognostic indicator for patients with CRC. Further studies are required to confirm these results.

키워드

참고문헌

  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  2. Conradi LC, Styczen H, Sprenger T, et al (2013). Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol, 37, 522-31. https://doi.org/10.1097/PAS.0b013e318272ff4d
  3. de Graeff P, Crijns AP, de Jong S, et al (2009). Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer, 101, 149-59. https://doi.org/10.1038/sj.bjc.6605112
  4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Egger M, Davey SG., Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  6. Essapen S, Thomas H, Green M, et al (2004). The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol, 24, 241-8.
  7. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S (2011). The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol, 22, 1308-17. https://doi.org/10.1093/annonc/mdq593
  8. Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  9. Huang Y, Li W, Chu D, et al (2011). Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer. J Gastrointest Surg, 15, 1188-94. https://doi.org/10.1007/s11605-011-1519-5
  10. Iivanainen E, Nelimarkka L, Elenius V, et al (2003). Angiopoietinregulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J, 17, 1609-21. https://doi.org/10.1096/fj.02-0939com
  11. Izumi Y, Xu L, di TE, Fukumura D, Jain RK (2002). Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416, 279-80.
  12. JemalA, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  13. Jesus EC, Matos D, Artigiani R, et al (2005). Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cir Bras, 20, 422-27.
  14. Kapitanovic S, Radosevic S, Kapitanovic M, et al (1997). The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology, 112, 1103-13. https://doi.org/10.1016/S0016-5085(97)70120-3
  15. Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401. https://doi.org/10.7314/APJCP.2012.13.12.6397
  16. Kavanagh DO, Chambers G., O'Grady L, et al (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer. BMC Cancer, 9, 1. https://doi.org/10.1186/1471-2407-9-1
  17. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D (1994). Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology, 25, 455-61. https://doi.org/10.1111/j.1365-2559.1994.tb00007.x
  18. Knosel T, Yu Y, Stein U, et al (2002). Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis, 19, 401-7. https://doi.org/10.1023/A:1016368708107
  19. Kountourakis P, Pavlakis K, Psyrri A, et al (2006). Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J, 12, 229-36. https://doi.org/10.1097/00130404-200605000-00012
  20. Kovacevic D, Sonicki Z, Kusic Z, et al (2007). Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer. Int J Colorectal Dis, 22, 827-31. https://doi.org/10.1007/s00384-006-0200-z
  21. Kruszewski WJ, Rzepko R, Ciesielski M, et al (2010). Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers, 29, 207-12. https://doi.org/10.1155/2010/109063
  22. Lazaris AC, Theodoropoulos G E, Anastassopoulos P, et al (1995). Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol, 10, 661-8.
  23. Li Q, Wang D, Li J, Chen P (2011). Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer, 11, 277. https://doi.org/10.1186/1471-2407-11-277
  24. Li YG., Geng X (2010). A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care, 19, 313-6.
  25. Lim SW, Kim HR, Kim HY, et al (2013). Over-expression of Her- 2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol, 36, 311-21. https://doi.org/10.1007/s13402-013-0136-6
  26. McKay JA, Loane JF, Ross VG, et al (2002). c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer, 86, 568-73. https://doi.org/10.1038/sj.bjc.6600127
  27. McShane LM, Altman DG, Sauerbrei W, et al (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer, 93, 387-91. https://doi.org/10.1038/sj.bjc.6602678
  28. Meert AP, Martin B, Paesmans M, et al (2003). The role of HER- 2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer, 89, 959-65. https://doi.org/10.1038/sj.bjc.6601252
  29. Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A (2009). Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis, 11, 157-61. https://doi.org/10.1111/j.1463-1318.2008.01556.x
  30. Molaei M, Pejhan S, Nayer BN, et al (2009). Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. Eur J Gastroenterol Hepatol, 21, 289-93. https://doi.org/10.1097/MEG.0b013e32830b82ba
  31. Neto AS, Tobias-Machado M, Wroclawski ML, et al (2010). Her- 2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol, 184, 842-50. https://doi.org/10.1016/j.juro.2010.04.077
  32. Ochs AM, Wong L, Kakani V, et al (2004). Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer, 4, 262-7. https://doi.org/10.3816/CCC.2004.n.025
  33. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008). Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer, 44, 946-53. https://doi.org/10.1016/j.ejca.2008.03.006
  34. Osako T, Miyahara M, Uchino S, et al (1998). Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology, 55, 548-55. https://doi.org/10.1159/000011911
  35. Pappas A, Lagoudianakis E, Seretis C, et al (2013). Clinical role of HER-2/neu expression in colorectal cancer. J BUON, 18, 98-104.
  36. Park DI, Kang MS, Oh SJ, et al (2007). HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis, 22, 491-7. https://doi.org/10.1007/s00384-006-0192-8
  37. Park YJ, Park KJ, et al (1999). Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg, 23, 721-6. https://doi.org/10.1007/PL00012376
  38. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  39. Ren H, Li J, Liu JJ, Guo HL, Jiang T (2012). Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo. Asian Pac J Cancer Prev, 13, 2795-8. https://doi.org/10.7314/APJCP.2012.13.6.2795
  40. Rossi HA, Liu Q, Banner B, et al (2002). The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J, 8, 268-75 https://doi.org/10.1097/00130404-200205000-00011
  41. Sanz-Casla MT, Vidaurreta M, Maestro ML, et al (2004). Prognostic significance of the p185 protein in colorectal cancer. Rev Esp Enferm Dig, 96, 102-9.
  42. Schuell B, Gruenberger T, Scheithauer W, Ch Z, Wrba F (2006). HER 2/neu protein expression in colorectal cancer. BMC Cancer, 6, 123. https://doi.org/10.1186/1471-2407-6-123
  43. Seidal T, Balaton AJ, Battifora H (2001). Interpretation and quantification of immunostains. Am J Surg Pathol, 25, 1204-7. https://doi.org/10.1097/00000478-200109000-00013
  44. Sun XF, Carstensen JM, Nordenskjold B (1995). Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. Anal Cell Pathol, 8, 203-11.
  45. Sun XF, Carstensen JM, Stal O, Zhang H, Nordenskjold B (1995). c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS, 103, 309-15. https://doi.org/10.1111/j.1699-0463.1995.tb01112.x
  46. Sung JJ, Lau JY, Goh KL, Leung WK (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol, 6, 871-6. https://doi.org/10.1016/S1470-2045(05)70422-8
  47. Thompson SG., Higgins JP (2002). How should meta-regression analyses be undertaken and interpreted. Stat Med, 21, 1559-73. https://doi.org/10.1002/sim.1187
  48. Tsigris C, Karayiannakis AJ, Zbar A, et al (2002). Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett, 184, 215-22. https://doi.org/10.1016/S0304-3835(02)00205-7
  49. Uner A, Ebinc FA, Akyurek N, et al (2005). Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol, 27, 225-8.
  50. Wang S, Zheng G., Chen L, Xiong B, (2011). Effect of HER-2/ neu over-expression on prognosis in gastric cancer: a metaanalysis. Asian Pac J Cancer Prev, 12, 1417-23.
  51. Wingens M, Walma T, van Ingen H, et al (2003). Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity. J Biol Chem, 278, 39114-23. https://doi.org/10.1074/jbc.M305603200
  52. Xiong Y, Fang Z, Zhang C, et al (2011). Copy number increase of HER-2 in colorectal cancers. Oncol Lett, 2, 331-5.

피인용 문헌

  1. Association of HER2 codon 655 polymorphism with ovarian cancer vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4609-2